A Study of LGD-6972 in Patients With Type 2 Diabetes Mellitus

Summary

The purpose of this study is to evaluate the change from baseline in hemoglobin A1c (HbA1c) during 12 weeks of treatment with 3 dose levels of LGD-6972 compared to placebo in subjects with Type 2 Diabetes Mellitus (T2DM)

Timeline

Start

2016-09

Primary completion

2017-06

Completion

2017-06

Publications

• Pettus JH, D'Alessio D, Frias JP, Vajda EG, Pipkin JD, Rosenstock J, Williamson G, Zangmeister MA, Zhi L, Marschke KB. Efficacy and Safety of the Glucagon Receptor Antagonist RVT-1502 in Type 2 Diabetes Uncontrolled on Metformin Monotherapy: A 12-Week Dose-Ranging Study. Diabetes Care. 2020 Jan;43(1):161-168. doi: 10.2337/dc19-1328. Epub 2019 Nov 6.

Drugs

Indications